Effect of serum uric acid on prognosis of drug-eluting stent implantation for patients with coronary bifurcated lesions

Abstract Purpose To investigate the effect of hyperuricemia on prognosis of drug-eluting stent implantation for patients with coronary bifurcated lesions. Materials and methods Patients with coronary bifurcation lesions treated with drug-eluting stent implantation were retrospectively enrolled. The clinical, interventional and follow-up data were analyzed. Results Totally, 193 patients were enrolled, including 59 with hyperuricemia and 134 without hyperuricemia. Serum triglyceride (1.73 vs. 1.44 mmol/L) and creatinine (70.0 vs. 61.0µmol/L) levels were significantly (P < 0.05) higher in the hyperuricemia than in the non-hyperuricemia group. During follow-up, seven patients died, including one (14.3%) death in the hyperuricemia and six (85.7%) in the non-hyperuricemia group. Twelve patients experienced revascularization, including 5 (41.7%) in the hyperuricemia group and 7 (58.3%) in the non-hyperuricemia group. Seventy patients were readmitted to the hospital because of cardiac reasons, including 36 (51.4%) patients in the hyperuricemia and 34 (48.6%) in the non-hyperuricemia group. The risk of cardiac readmission was significantly (P < 0.001) greater in the non-hyperuricemia than in the hyperuricemia group (30.10 vs. 24.33 m). Age was a significant (P = 0.01) independent risk factor for all-cause mortality after cardiac intervention with a hazard ratio (HR) of 1.12 (95% CI 1.03–1.23). Diabetes mellitus was the only significant (P = 0.007) independent risk factor for revascularization, with a HR of 5.13 (95% CI 1.56–16.91). Male sex (P = 0.023, HR 2.21 with 95% CI of 1.12–4.38), total cholesterol (P = 0.004, HR 2.53 with 95% CI 1.35–4.74), and hyperuricemia (P = 0.001, HR 2.37 with 95% CI 1.44–3.89) were significant independent risk factors for cardiac readmission. Conclusion Hyperuricemia is an independent risk factor for cardiogenic readmission rather than for all-cause mortality and revascularization after drug-eluting stent implantation for patients with coronary bifurcation lesions.